Familiar Therapeutics joins Clare Ventures Portfolio

Familiar Therapeutics has launched with $5 million in seed funding to bring the advances of modern human medicine to dogs and cats. Clare Ventures proudly joins the seed round via Icehouse Ventures, supporting the incredible team at Familiar as they set to translate proven human medicines into novel therapeutics and diagnostics for companion animals.

Founder Dr Elizabeth Iorns received the kind of news every pet owner dreads when her French Bulldog, Lily, had been diagnosed with a terminal brain tumor. As a cancer biologist who had spent her career at the frontier of human oncology, Elizabeth knew what modern targeted therapy could do. But for canine glioma, no such option existed, so Familiar Therapeutics was born!

Over the past two decades, a new generation of medicines has changed the outlook for people with chronic and life-threatening diseases. Dogs and cats develop many of the same diseases as people, often driven by the same underlying biology, yet very little of that medical progress has reached them. Fewer than 10 new drugs are approved by the FDA each year for companion animals, compared with more than 50 for people.

For many serious conditions, veterinarians still rely on human medicines used off-label, without dosing or safety data for the species. Much of the science needed to change this exists, but adapting a drug for animals takes its own clinical studies, manufacturing work and FDA review. Without a dedicated path for that work, promising medicines rarely make it across to dogs and cats.

Familiar was built to close that gap. Because each program starts with years of human research behind it, Familiar aims to bring disease-modifying medicines to pets significantly faster than the seven to ten years a new animal drug typically takes. The company works with pharmaceutical and biotech partners on each program, licensing the veterinary rights to their drugs and leading the clinical development and manufacturing work needed for FDA approval in dogs and cats.

In the five months since its founding, Familiar built a pipeline of four lead programs and nine earlier-stage programs for dogs and cats, signed multiple partnership and licensing agreements with biopharmaceutical companies, opened two investigational new animal drug (INAD) files with the FDA Center for Veterinary Medicine and filed one provisional patent. The seed funding will move its lead programs into clinical studies and advance the rest of its pipeline.

Familiar was founded by serial entrepreneurs Elizabeth Iorns, PhD, and Dan Knox, MBA. They previously co-founded Science Exchange, the Y Combinator-backed R&D outsourcing platform used by the world’s largest pharmaceutical companies, and led it through its acquisition in 2024. The gap between human and veterinary medicine became personal for Elizabeth in 2020, when her French Bulldog, Lily, was diagnosed with a terminal brain tumor. Elizabeth, a cancer biologist by training, worked through the research literature and found a checkpoint inhibitor that an academic team had tested in pet dogs with brain tumors, but no company had developed it for veterinary use. She and Dan licensed that therapy, partnered with Ardent Animal Health to combine it with their personalized cancer vaccine, and ran a registrational study in dogs with osteosarcoma that recently met its endpoint.

Elizabeth and Dan founded Familiar to bring many more of these medicines to pets, leading their development through approval and launch across multiple therapeutic areas.